Showing results (1301-1310 of 1,547) with videos related to

Sort By:
Pageof 155
Neuro-Oncology|January 14, 2025
Benchmarking the Efficacy of Salvage Systemic Therapies for Recurrent Meningioma: A RANO Group Systematic Review and Meta-analysis to Guide Clinical Trial DesignRupesh Kotecha, Eyub Y Akdemir, Tugce Kutuk, et al.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi = Chinese Journal of Schistosomiasis Control|March 4, 2021
[Expert consensus on the strategy and measures to interrupt the transmission of schistosomiasis in China]S Lü, C Lü, Y L Li, et al.
Journal of Neuro-Oncology|August 29, 2019
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201Andrew S Chi, Rohinton S Tarapore, Matthew D Hall, et al.
Cancer Discovery|November 8, 2011
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathwayDeliang Guo, Felicia Reinitz, Mary Youssef, et al.
The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO groupNancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, et al.
Neuro-Oncology|May 20, 2021
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial resultsWenya Linda Bi, Lakshmi Nayak, David M Meredith, et al.
Pigment Cell & Melanoma Research|August 1, 2022
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesAlcida Karz, Maya Dimitrova, Kevin Kleffman, et al.
Neuro-Oncology|December 26, 2024
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Mehdi Touat, Martin J van den Bent, et al.
Neuro-Oncology|July 31, 2024
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patientsMary Jane Lim-Fat, Jennifer A Cotter, Mehdi Touat, et al.
Neuro-Oncology|April 28, 2025
Establishing the content validity of Patient-Reported Outcome measures used in neuro-oncology based on the WHO ICF framework: part of the RANO-PRO initiativeOgechukwu A Asogwa, Linda Dirven, Tobias Walbert, et al.
Pageof 155